ICRF 197

Drug Profile

ICRF 197

Latest Information Update: 29 Jan 2015

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer BTG; Nonindustrial source
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chemoprotection

Most Recent Events

  • 01 Nov 1999 ICRF 197 is available for licensing
  • 28 May 1999 New profile
  • 28 May 1999 Preclinical development for Chemotherapy induced damage/Chemoprotection in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top